Genetic testing company Syantra has obtained CE marking for its flagship product, the Syantra DXTM Breast Cancer test. The CE marking will allow the company to market the blood test in the EU and other countries that recognize the designation.

Syantra DXTM Breast Cancer is a minimally invasive blood test that evaluates 12 gene expression biomarkers using proprietary software and machine-learning-derived algorithms to interpret the data. It detects active breast cancer in its earliest stages, making treatment easier. Syantra claims that its test may improve detection, especially for high-risk individuals, such as those with genetic predisposition, dense breasts, or diverse ethnic backgrounds, for whom mammograms may be inadequate.

Syantra Inc. is a biotech company that uses its flagship blood test, Syantra DXTM Breast Cancer, for the early detection of breast cancer to help optimize treatment. Syantra also uses its discovery platform, which includes the FlowPlate device, biobank, and clinical and molecular profile database, to identify novel biomarkers and drug targets. Syantra's platform focuses on drug target validation and testing using human cellular disease models to support candidate selection for clinical trials.